Curis (CRIS) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $1.7 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | PMCB |
|---|---|---|
| Share price | $0.7094 | $0.3974 |
| Market cap | $1.72M | $4.27M |
| 1-day change | -3.69% | -2.02% |
| P/E ratio (TTM) | 0.54 | — |
| EPS (TTM) | $1.32 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $1.51 |
| 52-week low | $0.61 | $0.3339 |
| Distance from 52-week high | -97.89% | -73.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +5914.94% | — |
| Average volume | 199.15K | 205.72K |
| Shares outstanding | 2.43M | 10.74M |
| Employees | 20 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PharmaCyte Biotech is about 2.5 times larger than Curis by market value ($4.27M vs $1.72M).
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
CRIS vs PMCB FAQ
Which is bigger, Curis or PharmaCyte Biotech?
PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $1.72M for Curis (CRIS).
Are Curis and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.